Quick Answer
Boron Sleep Meta-Analysis has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: Objective To test the feasibility of a smartphone app, BebeApp, that provides evidence-based early childhood development (ECD) guidance in rural Guatemala and pilot procedures for an adequately powered randomised controlled trial.
Key Takeaways
- 01Objective To test the feasibility of a smartphone app, BebeApp, that provides evidence-based early childhood development (ECD) guidance in rural Guatemala and pilot procedures for an adequately powered randomised controlled trial. [Tschida S (2026)]
- 02Interventions BebeApp provides age-dependent, evidence-based caregiver guidance for breastfeeding and complementary feeding, sleep and developmental support. [Tschida S (2026)]
- 03Usability was found to be acceptable but no difference was found between pre-measurements and post-measurements. [Tschida S (2026)]
- 04Design We conducted an individually randomised pilot feasibility trial to compare BebeApp to printed ECD guidance. [Tschida S (2026)]
The current Migaku evidence database contains 2 reusable source documents for Boron Sleep Meta-Analysis. This answer focuses on safety, limits, and clinician-discussion contexts.
- Objective To test the feasibility of a smartphone app, BebeApp, that provides evidence-based early childhood development (ECD) guidance in rural Guatemala and pilot procedures for an adequately powered randomised controlled trial. [Tschida S (2026); evidence level 2]
- Interventions BebeApp provides age-dependent, evidence-based caregiver guidance for breastfeeding and complementary feeding, sleep and developmental support. [Tschida S (2026); evidence level 2]
- Usability was found to be acceptable but no difference was found between pre-measurements and post-measurements. [Tschida S (2026); evidence level 2]
- Design We conducted an individually randomised pilot feasibility trial to compare BebeApp to printed ECD guidance. [Tschida S (2026); evidence level 2]
- While a gradual decline in testosterone with advancing age is well recognized—most notably in men aged 70–80 years, and progressively in women during the premenopausal period with a stabilization or a modest increase after menopause [,]—cumulative evidence has documented an additional, age-independent decline in men. [Fraile-Martínez Óscar (2026); evidence level 3]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources